Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia.
Front Immunol
; 13: 1055473, 2022.
Article
em En
| MEDLINE
| ID: mdl-36524117
ABSTRACT
Daratumumab, a CD38 monoclonal antibody that has been FDA-approved to treat multiple myeloma, has acquired popularity and is used off-label for both auto- and alloantibody mediated disorders, particularly in refractory/resistant circumstances. Much of the published data for its use in pediatric blood disorders has been in post-transplant autoimmune cytopenias. Here we describe three patients in whom daratumumab was used outside of post-transplant autoimmune cytopenias, highlighting further potential uses of this medication.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Anemia Hemolítica Autoimune
/
Mieloma Múltiplo
Tipo de estudo:
Etiology_studies
Limite:
Child
/
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article